Objective: To develop an instrument of lymphoma symptom assessment and to test its reliability and validity based on the specific symptoms of lymphoma and various therapeutic responses.Methods:Based on literature review, semi-structured interviews and existing symptom assessment tools of cancer patients, the item pool of patients with lymphoma were summarized. Through two rounds of expert interrogation, lymphoma symptom assessment scale was established. 150 patients with pre-treatment and in-treatment were evaluated using the lymphoma symptom assessment scale and the M.D. Anderson symptom assessment scale, for testing the validity and reliability. Results: The lymphoma symptom assessment scale included 23 items, the I-CVI for each symptom entry ranged from 0.750 to 1.000 and the S-CVI / Ave for the content-validity of the scale was 0.900; exploratory factor analysis extracted 6 common factors, the cumulative contribution rate was 69.63% .There were 6 dimensions named gastrointestinal tract reactions, other side effects, systemic symptoms, mood-sleep, pain-related symptoms, skin reactions. Using MDASI-PartII as the benchmarking tool, the total score of the assessment scale and the MDASI-Partll score were statistically significant with a correlation coefficient of 0.688(P<0.01). The total scale Cronbach’s coefficient was 0.812; Cronbach’s coefficient of 6 common factors ranged from 0.770 to 0.899. Conclusion: Thelymphoma symptom assessment scale has good reliability and validity, which can be used as a tool to assess the symptoms of lymphoma patients.